SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that Amber Salzman, Ph.D., chief executive officer, will participate in a panel discussion at the BMO Biopharma Spotlight Series: Latest Advances in Genome / Epigenome Editing virtual event. The panel, titled “Latest Advances in Epigenetic Editing,” will be held Tuesday September 26, 2023 at 1:00 p.m. ET.
The event will be made available live only to clients of BMO. Institutional investors interested in meeting with management during the conference may reach out to their BMO representative.
About Epic Bio
Epic Bio is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo delivery via a single AAV vector. Epic’s lead program, EPI-321, is in IND-enabling studies for treatment of facioscapulohumeral muscular dystrophy (FSHD); additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn.
CONTACT: Investor Contact Shawn M. Cox Epic Bio Manager, Investor Relations, Corporate Communications Shawn.cox@epic-bio.com Media Contact Lisa Raffensperger Ten Bridge Communications lisa@tenbridgecommunications.com (617) 903-8783
- U.S. Medical Coding Market to generate Demand to a Valuation of USD 44 Billion by 2032 || Growing at a CAGR of 9.4% - October 3, 2023
- Solar Powered Vehicles Market on Track to Achieve USD 2,543 million by 2032 || Noteworthy CAGR of 21.0% - October 3, 2023
- Sports Bra Market Size is Projected to Reach USD 101.3 Billion by 2030, Growing at a CAGR of 12.5%: Zion Market Research - October 3, 2023
